DE3881801D1 - Menschliche somatomedin-traeger-protein-untereinheiten und verfahren zu ihrer herstellung. - Google Patents

Menschliche somatomedin-traeger-protein-untereinheiten und verfahren zu ihrer herstellung.

Info

Publication number
DE3881801D1
DE3881801D1 DE8888904042T DE3881801T DE3881801D1 DE 3881801 D1 DE3881801 D1 DE 3881801D1 DE 8888904042 T DE8888904042 T DE 8888904042T DE 3881801 T DE3881801 T DE 3881801T DE 3881801 D1 DE3881801 D1 DE 3881801D1
Authority
DE
Germany
Prior art keywords
carrier
units
production
human
somatomedin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8888904042T
Other languages
English (en)
Other versions
DE3881801T2 (de
Inventor
Emerald Spencer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Publication of DE3881801D1 publication Critical patent/DE3881801D1/de
Application granted granted Critical
Publication of DE3881801T2 publication Critical patent/DE3881801T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE88904042T 1987-04-06 1988-03-31 Menschliche somatomedin-träger-protein-untereinheiten und verfahren zu ihrer herstellung. Expired - Fee Related DE3881801T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3488587A 1987-04-06 1987-04-06

Publications (2)

Publication Number Publication Date
DE3881801D1 true DE3881801D1 (de) 1993-07-22
DE3881801T2 DE3881801T2 (de) 1993-12-23

Family

ID=21879212

Family Applications (1)

Application Number Title Priority Date Filing Date
DE88904042T Expired - Fee Related DE3881801T2 (de) 1987-04-06 1988-03-31 Menschliche somatomedin-träger-protein-untereinheiten und verfahren zu ihrer herstellung.

Country Status (11)

Country Link
EP (2) EP0308500B1 (de)
JP (1) JP2648951B2 (de)
AT (1) ATE90690T1 (de)
AU (1) AU627423B2 (de)
CA (1) CA1340295C (de)
DE (1) DE3881801T2 (de)
DK (1) DK677688D0 (de)
ES (1) ES2058341T3 (de)
IL (1) IL85983A (de)
WO (1) WO1988007863A1 (de)
ZA (1) ZA882407B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5973115A (en) * 1987-05-15 1999-10-26 Amgen Inc. Method for potentiating and inhibiting insulin-like growth factor activity
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
AU1955388A (en) * 1988-04-12 1989-11-03 Synergen, Inc. Method for potentiating and inhibiting insulin-like growth factor activity
EP0424416B1 (de) * 1988-07-15 1995-07-19 Central Sydney Area Health Service Säureempfindliche subeinheit eines insulinähnlichen wachstumfaktors-bindeprotein-komplexes
US6465423B1 (en) 1988-07-15 2002-10-15 Central Sydney Area Health Service Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
US5324820A (en) * 1988-07-15 1994-06-28 Central Sydney Area Health Service Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
EP0800530A4 (de) * 1994-07-20 1998-12-02 Celtrix Pharma Igf/igfbp-komplex zur förderung der knochenentwicklung und zur regulation des knochenumbaus
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
EP1282437B1 (de) 2000-05-16 2008-03-19 Genentech, Inc. Behandlung von knorpelerkrankungen
EP1401476A4 (de) 2001-03-14 2006-03-08 Genentech Inc Igf-antagonistenpeptide
EP1622942B1 (de) 2003-05-01 2014-11-19 ImClone LLC Komplett menschliche antikörper gegen den rezeptor des insulin-ähnlichen wachstumsfaktor i
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
JP2007537711A (ja) 2003-10-03 2007-12-27 ジェネンテック・インコーポレーテッド Ｉｇｆ結合タンパク質
US8128929B2 (en) 2005-06-17 2012-03-06 Imclone Llc Antibodies against PDGFRa
AP2008004569A0 (en) 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
EA202090705A1 (ru) 2017-09-11 2020-06-11 Шайр Хьюман Дженетик Терапиз, Инк. Способы и композиции, предназначенные для лечения хронических заболеваний легких
CA3194764A1 (en) 2020-10-19 2022-04-28 Oak Hill Bio Limited Compositions suitable for use in neonates
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
WO2023242439A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)
WO2023242442A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2023242440A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants

Also Published As

Publication number Publication date
IL85983A (en) 1994-10-07
ES2058341T3 (es) 1994-11-01
WO1988007863A1 (en) 1988-10-20
AU1702088A (en) 1988-11-04
JPH01502986A (ja) 1989-10-12
EP0308500B1 (de) 1993-06-16
DE3881801T2 (de) 1993-12-23
DK677688A (da) 1988-12-05
EP0294021A1 (de) 1988-12-07
AU627423B2 (en) 1992-08-27
DK677688D0 (da) 1988-12-05
JP2648951B2 (ja) 1997-09-03
IL85983A0 (en) 1988-09-30
CA1340295C (en) 1998-12-29
ZA882407B (en) 1988-09-28
EP0308500A1 (de) 1989-03-29
ATE90690T1 (de) 1993-07-15

Similar Documents

Publication Publication Date Title
DE3881801D1 (de) Menschliche somatomedin-traeger-protein-untereinheiten und verfahren zu ihrer herstellung.
ZA899832B (en) Human somatomedin carrier protein subunits and process for producing them;recombinant dna molecules,hosts,processes and human somatomedian carrier protein-like polypeptides
PT92278A (pt) Processo para a preparacao de proteinas de ligacao de factor de crescimento semelhante a insulina
ATE257516T1 (de) Nukleotidsequenzen, die für ein protein mit ureaseaktivität kodieren
DE3882055D1 (de) Verfahren zur herstellung von pyridin-2,3-dicarboxylsaeure-verbindungen.
FI97299C (fi) Menetelmä kimeerisen transformoivan beta-kasvutekijän valmistamiseksi
DE69319012D1 (de) Protein mit Knochenbildungs-Eigenschaften und Verfahren zu seiner Herstellung
ATE186781T1 (de) Verfahren zur herstellung von testelementen
AU576508B2 (en) Sythetic peptides antigenically corresponding to brain specific proteinoids
ATE127478T1 (de) Onkogen kodierendes polypeptid, das wachstumsfaktoraktivität besitzt, verfahren zu seiner herstellung und verwendung.
ATE81013T1 (de) Verfahren zur herstellung von faktor viii:cmangelplasma und ein so erhaltenes mangelplasma.
DE68923232D1 (de) Verfahren zur herstellung von pyridin-2,3-dicarbonsäure-verbindungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee